Top Page
Vicore Pharma Holding AB
(VICO)
Vicore Pharma Holding AB (VICO) vs. iShares MSCI Sweden ETF (EWD)
Vicore Pharma Holding AB Business Overview & Revenue Model
Vicore Pharma Holding AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.74M | 109.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.18M | 109.35M | -3.42M | -3.61M | -3.60M | -3.54M |
| EBITDA | -326.18M | -166.64M | -317.47M | -286.20M | -289.82M | -143.77M |
| Net Income | -370.92M | -168.63M | -310.94M | -288.42M | -296.48M | -146.86M |
Balance Sheet | ||||||
| Total Assets | 976.50M | 1.20B | 497.84M | 338.01M | 451.17M | 406.51M |
| Cash, Cash Equivalents and Short-Term Investments | 936.98M | 1.16B | 482.66M | 261.74M | 371.20M | 318.62M |
| Total Debt | 0.00 | 0.00 | 0.00 | 65.00K | 320.00K | 140.00K |
| Total Liabilities | 68.25M | 73.78M | 42.45M | 48.92M | 67.85M | 52.00M |
| Stockholders Equity | 908.25M | 1.13B | 455.39M | 289.08M | 383.32M | 354.51M |
Cash Flow | ||||||
| Free Cash Flow | -331.04M | -164.95M | -448.62M | -302.92M | -265.17M | -122.94M |
| Operating Cash Flow | -331.04M | -164.95M | -249.58M | -299.92M | -265.17M | -119.94M |
| Investing Cash Flow | -480.29M | 149.04M | -144.46M | 74.00M | -7.00M | 4.00M |
| Financing Cash Flow | 834.07M | 834.06M | 470.86M | 187.04M | 318.18M | 176.97M |
Vicore Pharma Holding AB Technical Analysis
Vicore Pharma Holding AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | kr1.36B | 10.79 | 81.19% | ― | ― | ― | |
58 Neutral | kr3.14B | -6.06 | -71.87% | ― | -91.85% | -6.65% | |
58 Neutral | kr1.95B | -6.01 | -36.52% | ― | 533.73% | 20.92% | |
56 Neutral | kr1.11B | -9.50 | -58.41% | ― | ― | 48.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr3.76B | -4.15 | ― | ― | -5.69% | 21.58% | |
42 Neutral | kr1.02B | -4.17 | -35.03% | ― | ― | 25.14% |
Vicore Pharma Holding AB Corporate Events
Vicore Pharma announced that its senior leadership team will present and hold one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026, with the session also accessible via webcast. Participation in this high-profile investor event underscores the company’s efforts to raise its visibility within the global healthcare investment community and could support partnering and financing opportunities as it advances its ATRAG-based pipeline and lead IPF program, buloxibutid.
The most recent analyst rating on (SE:VICO) stock is a Hold with a SEK12.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
Vicore Pharma Holding AB will be moved from Nasdaq Stockholm’s Small Cap to the Mid Cap segment following Nasdaq’s annual review of Nordic market capitalization segments, with the reclassification taking effect on January 2, 2026. The move to the Mid Cap segment reflects the company’s increased market value and may enhance its visibility among investors and within the Nordic life sciences sector, potentially supporting broader interest in its clinical pipeline and long-term growth prospects.
Vicore Pharma Holding AB announced its participation in the Oppenheimer Movers in Rare Disease Summit, where they will engage in a fireside chat and one-on-one meetings. This participation highlights Vicore’s ongoing efforts to position itself as a leader in the development of novel treatments for rare diseases, potentially enhancing its visibility and stakeholder engagement in the pharmaceutical industry.
Vicore Pharma Holding AB has announced an increase in its number of shares and votes following a directed share issue, raising approximately USD 48 million. This development increases the company’s share capital and strengthens its financial position, potentially enhancing its ability to advance its drug development programs and maintain its competitive edge in the pharmaceutical industry.
Vicore Pharma announced its participation in the DNB Carnegie Nordic Healthcare Conference in Oslo, where CFO Hans Jeppsson will present and engage in one-on-one meetings. This participation underscores Vicore’s active engagement with the healthcare investment community, potentially enhancing its visibility and fostering strategic partnerships.
Vicore Pharma announced its participation in the Jefferies Global Healthcare Conference in London, where key executives will present and engage in one-on-one meetings. This event provides an opportunity for Vicore to showcase its innovative drug programs and strengthen its industry presence, potentially impacting its market positioning and stakeholder engagement.
Vicore Pharma Holding AB has successfully raised approximately USD 48 million through a directed share issue, which was oversubscribed by institutional healthcare investors. The funds will primarily be used to expand the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis, increasing the sample size to enhance the trial’s statistical power and potential for success. This strategic move aims to position Vicore as a leader in developing disease-modifying treatments for IPF, with the trial’s completion expected in the first half of 2026.
Vicore Pharma Holding AB announced a directed share issue to raise approximately USD 40 million through an accelerated bookbuilding process targeting institutional investors. The proceeds will primarily fund the expansion of the Phase 2b ASPIRE trial for buloxibutid, enhancing its potential as a disease-modifying treatment for IPF. This strategic move aims to strengthen Vicore’s financial position, diversify its shareholder base, and support future clinical and commercial activities.
Vicore Pharma Holding AB announced its participation in two major healthcare conferences in the USA, where the company’s CEO and VP of IR will present and engage in meetings. This participation highlights Vicore’s strategic efforts to engage with investors and stakeholders, potentially enhancing its visibility and positioning in the pharmaceutical industry.
Vicore Pharma Holding AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting, comprising representatives from its three largest shareholders and the company’s chairman. This committee is tasked with preparing proposals for board elections, remuneration, and auditor appointments for the AGM scheduled for May 6, 2026. The announcement underscores Vicore’s commitment to structured governance and stakeholder engagement as it continues to advance its pharmaceutical innovations.